Enterprise Value

843.7M

Cash

322.2M

Avg Qtr Burn

-41.73M

Short % of Float

28.50%

Insider Ownership

8.99%

Institutional Own.

90.81%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
VOQUEZNA (Vonoprazan)(Potassium competitive acid blocker) Details
Intestinal infection, Gastroesophageal reflux disease, Esophagitis

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Phase 3

Initiation

Phase 2

Initiation